(Total Views: 141)
Posted On: 12/08/2021 1:15:57 PM
Post# of 27072

$AFMD News Article - Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche's Anti-PD-L1 Checkpoint Inhibitor Atezolizumab https://marketwirenews.com/news-releases/affi...93371.html


My Twitter: WhyteStocks